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Impact factor (IF) – an index of citations of arti‑
cles in the 2 years subsequent to publication in 
a journal1 – is a measure used for ranking jour‑
nal quality.2 It is also an important issue for au‑
thors to consider when selecting journals for 
manuscript submission1: those with higher IFs 
are often considered more prestigious. The val‑
ues of IF vary widely between journals. While 
a few journals have very high IFs (CA: A Cancer 
Journal for Clinicians, IF 101.78 in 2011; The New 
England Journal of Medicine, 53.298; and the An-
nual Review of Immunology, 52.761),3 most have 
IFs between 1 and 2, and many have IFs well un‑
der 1.4 A journal of IF over 4 is often considered 
of good quality.4
IF is sometimes used for evaluating the quali‑
ty of individual articles and researchers. However, 
the fact that 50% of the articles that are most cit‑
ed in a journal often account for 90% of a journal’s 
IF suggests that a journal’s IF is unlikely to repre‑
sent the quality of individual articles or research‑
ers.2 This approach has received criticism.2
Several empirical studies have examined the is‑
sue about the quality of journal publications and 
their IFs. Most of them compared methodologi‑
cal characteristics of randomized controlled tri‑
als (RCTs) published in higher vs. lower impact 
journals. Some of these studies revealed differ‑
ences in the two journal categories: higher im‑
pact journals more likely publish RCTs of larger 
sample sizes, better methodological quality,5,6 in‑
creased probability of publishing positive RCTs,7 
and with more frequent reporting of statistical 
information (for example, effect size, precision, 
sample size, and power calculations).8
A recent systematic survey examined meth‑
odological characteristics of a large sample of 
RCTs published in higher vs. lower impact jour‑
nals.9 This survey covered a broad range of RCTs 
published in the Core Clinical Journals in 2007, 
which was defined by the National Library of 
Medicine. The group of higher impact journals 
included the Annals of Internal Medicine, British 
Medical Journal, Journal of the American Medical 
Association, Lancet, and The New England Journal of 
Medicine. This study found that trials in higher im‑
pact journals enrolled more participants and were 
more likely to receive industry funding. The re‑
porting of information regarding methodological 
quality, although better in higher impact journals, 
was insufficient in both groups of journals. For 
instance, allocation concealment was not report‑
ed in 34% of the trials in higher impact journals, 
and the proportion was even higher (64%) in low‑
er impact journals, while failure to conceal treat‑
ment allocation is associated with bias.10
This study also found that trials often used sur‑
rogate markers, rather than patient‑important 
outcomes, for the assessment of treatment effects, 
as the effect may be more apparent in the use of 
surrogate outcomes. However, treatment effects 
on patient‑important outcomes may be small 
and uncertain even with large effects on surro‑
gate markers.11 Previous studies have shown that 
only a small proportion of trials (11% to 23%) re‑
ported patient‑important primary outcomes.12,13 
This study further found that patient‑important 
primary outcomes appeared to be more common‑
ly reported in higher vs. lower impact journals 
(69% vs. 50%)9, and continuous outcomes were 
more common in lower impact journals, likely 
as a result of using surrogate markers of clini‑
cal events.
The Polish Archives of Internal Medicine (Pol Arch 
Med Wewn) received its first IF of 1.367 in June 
2012, placing the journal on the ninth place of 37 
Polish biomedical journals with an IF. This is con‑
sidered a great success of the journal and the Pol‑
ish Society of Internal Medicine.14 One may ask: 
are the findings from previous studies applica‑
ble to this journal? In an effort to critically ap‑
praise the quality of trials in the Pol Arch Med 
Wewn, we searched for RCTs published in the past 
2 years and found only 2 trials.15,16 Sample sizes 
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of these 2 trials were small (n = 33) or moder‑
ate (n = 260). Only one of those studies report‑
ed the source of funding.16 None of the studies 
reported information regarding randomization 
and treatment concealment of allocation, mak‑
ing the judgment about the validity of random‑
ization impossible. Blinding was not applied to 
the parties involved in the 2 trials (e.g.,  care 
providers, patients) except outcome assessors 
in 1 trial.16 None of the studies reported infor‑
mation regarding the completeness of follow‑ 
‑up, and patient‑important outcome was reported 
in 1 trial.16 Generally, the methodological quality 
of the 2 trials appeared suboptimal and the valid‑
ity of effect estimates may be questionable. De‑
spite the small number of observations, the find‑
ings signal that problems mentioned in the pre‑
vious studies is probably applicable to the trials 
published in the Pol Arch Med Wewn.
We also found that the vast majority of pub‑
lications in this journal were nonrandomized 
studies. Of the 87 original articles published in 
the past 2 years, 82 were nonrandomized stud‑
ies, predominantly observational studies. Previ‑
ous studies have shown that lower impact jour‑
nals, compared with higher impact journals, pub‑
lished fewer RCTs but more observational stud‑
ies7; RCTs constituted 12% and 35% of the pub‑
lished studies,  respectively.8 It seems that the Pol 
Arch Med Wewn publishes even a higher propor‑
tion of observational studies than that observed 
in previous reviews. For journals from lower in‑
come countries such as Poland, expensive RCTs 
are probably uncommon. As a result, the publi‑
cation of RCTs may be reasonably less frequent 
in such journals. However, the inherent limita‑
tions of nonrandomized studies (e.g., inability to 
randomly allocate patients to control unknown 
confounding factors) pose more serious threats 
to the validity of results.17
What do these findings imply? First, all the 
above findings suggest that there are important 
methodological limitations in RCTs published 
both in higher and lower impact journals, al‑
though those published in higher impact jour‑
nals may have relatively better methodological 
quality. An RCT published in higher impact jour‑
nal may not guarantee the credibility of the re‑
sults. Moreover, readers should appropriately as‑
sess the credibility of the results and cautiously 
apply findings from RCTs published both in high‑
er and lower impact journals. Researchers should 
design and conduct studies more rigorously, and 
report the results in more detail, regardless of 
RCTs and nonrandomized studies. Editors should 
always consider the improvement of the quality 
of a publication as a top priority. Finally, authors 
should look beyond a journal’s impact factor in 
the selection of target journals.
